Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

LivaNova stock price, quote, forecast and news

LIVN
GB00BYMT0J19
A14156

Price

50.75
Today +/-
-0.43
Today %
-0.94 %
P

LivaNova stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the LivaNova stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the LivaNova stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the LivaNova stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze LivaNova's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

LivaNova Stock Price History

DateLivaNova Price
9/20/202450.75 undefined
9/19/202451.23 undefined
9/18/202451.07 undefined
9/17/202451.00 undefined
9/16/202448.79 undefined
9/13/202448.53 undefined
9/12/202448.74 undefined
9/11/202447.45 undefined
9/10/202446.99 undefined
9/9/202447.09 undefined
9/6/202447.06 undefined
9/5/202447.01 undefined
9/4/202449.08 undefined
9/3/202449.58 undefined
8/30/202450.39 undefined
8/29/202450.24 undefined
8/28/202448.34 undefined
8/27/202446.60 undefined
8/26/202446.63 undefined

LivaNova Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into LivaNova, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by LivaNova from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects LivaNova’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of LivaNova. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into LivaNova’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing LivaNova’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on LivaNova’s growth potential.

LivaNova Revenue, EBIT and net profit per share

DateLivaNova RevenueLivaNova EBITLivaNova Net Income
2028e1.5 B undefined368.53 M undefined274.16 M undefined
2027e1.43 B undefined323.8 M undefined241.48 M undefined
2026e1.4 B undefined275.1 M undefined215.61 M undefined
2025e1.32 B undefined246.87 M undefined198.37 M undefined
2024e1.26 B undefined224.01 M undefined174.02 M undefined
20231.15 B undefined56.95 M undefined17.55 M undefined
20221.02 B undefined81.56 M undefined-86.25 M undefined
20211.04 B undefined47 M undefined-135.82 M undefined
2020934.24 M undefined-54.23 M undefined-348.82 M undefined
20191.08 B undefined58.87 M undefined-157.64 M undefined
20181.11 B undefined88.84 M undefined-189.4 M undefined
20171.01 B undefined126.99 M undefined-25.09 M undefined
2016964.86 M undefined88.93 M undefined-62.79 M undefined
2015415.71 M undefined41.53 M undefined-29.61 M undefined
2014291.56 M undefined97.34 M undefined57.85 M undefined
2013282.01 M undefined87.46 M undefined54.89 M undefined
2012254.32 M undefined78.35 M undefined46.36 M undefined
2011218.5 M undefined60.94 M undefined36.08 M undefined
2010190.46 M undefined49.19 M undefined46.73 M undefined
2009167.78 M undefined36.86 M undefined78.45 M undefined
2008143.6 M undefined18.99 M undefined26.72 M undefined
2007121.23 M undefined-8.23 M undefined-10.34 M undefined
2006130.97 M undefined-49.53 M undefined-51.18 M undefined
2005123.44 M undefined-59.23 M undefined-59.07 M undefined
2004103.44 M undefined-19.3 M undefined-18.61 M undefined

LivaNova Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
0000000000.010.030.050.040.070.10.110.10.120.130.120.140.170.190.220.250.280.290.420.961.011.111.080.931.041.021.151.261.321.41.431.5
---------1,300.00107.1462.07-8.5162.7948.575.77-6.3619.425.69-6.9218.1816.7813.7714.7416.5111.023.1942.61132.294.989.29-1.99-13.8410.81-1.3512.938.935.105.682.514.62
-------100.00100.0078.5775.8676.6072.0980.0084.6285.4584.4786.9986.1582.6486.0187.4387.8990.8391.3490.0790.7264.1057.9964.3366.3766.7063.6068.1269.2566.87-----
000000011112236315688948710711210012314616719823225426426655965173472359470570777100000
0-1-3-3-5-6-7-10-11-16-14-5-19-2904-19-59-49-81836496078879741881268858-54468156224246275323368
--------1,000.00-1,100.00-114.29-48.28-10.64-44.19-41.43-3.64-18.45-47.97-37.69-6.6112.5921.5625.7927.5230.7130.8533.339.889.1312.457.965.35-5.784.447.934.8617.8318.6419.7122.5924.60
0-1-3-3-5-5-7-10-11-14-12-3-24-2804-18-59-51-1026784636465457-29-62-25-189-157-348-135-8617174198215241274
--200.00-66.67-40.0042.8610.0027.27-14.29-75.00700.0016.67---550.00227.78-13.56-80.39-360.00200.00-41.03-21.7427.7817.395.56-150.88113.79-59.68656.00-16.93121.66-61.21-36.30-119.77923.5313.798.5912.0913.69
3.345.115.736.537.888.959.229.5112.0316.1117.518.0519.3821.6622.0425.9624.0424.9225.5126.5727.5428.728.6128.3128.0127.4726.6332.7448.8648.1648.548.3548.5950.6353.4754.2100000
-----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The LivaNova Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the LivaNova is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                   
1.223.3721.0810.149.892.127.9138.0420.7720.1457.1438.243.5858.3661.4892.3684.8173.7166.2359.2389.3196.65135.71128.33151.21119.6139.7993.6247.261.14252.83207.99214.17266.5
000.020.070.340.470.555.865.458.296.6410.3314.1716.9516.4821.3418.91299.6322.2526.1928.5829.2739.4550.6750.57272.35213.26282.15256.14257.77184.36185.35183.11215.07
0000000000000000000000000000000000
00.140.20.430.610.671.012.15.26.644.254.536.217.798.5517.3117.58192.7312.8414.2115.2714.3917.7217.6323.96212.45133.02144.47153.54164.15115.29105.84129.38147.89
0.050.080.080.220.270.260.131.160.91.421.381.31.352.663.366.274.1396.263.2215.6218.4420.814.4823.814.9869426.63349.6376.4266.38155.57180359.48358.7
1.273.5921.3710.8611.113.539.5947.1632.3136.4869.454.3565.2985.7789.85137.28125.43662.34104.53115.24151.6161.1207.36220.43240.72673.41812.69869.86533.3549.44708.04679.18886.14988.16
0.210.480.510.550.480.330.363.153.287.478.659.89.598.358.8510.328.03245.015.617.518.222.1628.5639.5440.29244.59203.71192.36191.4235.73214.33190.67183.02205.03
003.318.331.960.080.212.114.090.40.1100000072.22005.219.5110.5915.9417.1377.4956.2334.4924.8227.2631.0916.616.2722.84
0000000000000000000000000000000000
00000000000000000659.2901.955.244.519.2211.6610.17658.94441.61535.4770.44607.55437.64399.68368.56261.18
00000000000000000731.170000000745.36691.71784.24956.82915.79922.32899.53768.79782.94
0.010.020.010.020.010.010.080.190.110.160.150.170.230.180.154.74.19154.851.931.0641.2214.638.326.637.64158.95136.6987.5472.9376.0386.5415.372.01169.42
0000.010000.010.010.010.010.010.010.010.010.020.011.860.010.040.060.050.060.070.081.891.531.632.021.861.691.521.411.44
000.030.020.0100.010.050.040.040.080.060.080.090.10.150.142.520.110.160.210.210.260.290.322.562.342.52.552.412.42.22.292.43
                                                                   
5.5612.560.090.090.10.10.130.170.180.190.220.220.220.240.250.260.2775.730.280.290.30.310.310.320.3275.4474.5874.7576.1476.2676.382.382.4282.53
000.040.040.040.040.060.110.110.120.170.170.170.190.230.270.291.760.280.290.330.350.380.430.451.741.721.741.711.731.772.122.162.19
-6.03-9.52-14.64-20.57-27.81-37.92-49.17-63.34-75.88-78.93-103.63-129.75-124.57-117.81-148.4-207.47-258.6516.79-242.52-164.07-117.35-81.27-34.9119.9877.8348.21-14.58-39.66-251.58-406.76-761.97-897.78-984.03-966.48
0-0.41-0.31-0.22-0.170.030.120.11-0.13-0.17-2.11-1.71-1.47-1.44-3.45-48.02-38.5-24.91-0.24-0.06-0.570.420.170.46-3.4-54.23-68.4945.31-24.48-19.3927.81-7.18-48.12-27.88
00000000000000000-4.200000000.93.6-0.9-0.90.52.3000
-000.020.020.0100.010.040.030.040.060.040.050.070.080.01-0.011.820.040.130.210.270.350.450.521.811.721.811.51.391.111.31.211.28
0.270.390.180.280.580.920.373.691.71.84.875.635.424.446.625.195.95121.153.054.24.124.898.587.577.25109.5971.9385.9276.7485.8973.676874.3180.85
0.480.290.560.791.41.511.464.234.633.6913.2915.1812.5410.7113.3812.6614.84126.1614.619.1317.9718.1520.4522.3324.2136.83127.74143.87201.77186.93139.92159.78137.56187.32
00000.090.05000000000.051.180.1227.73000000030.19102.5792.2189.44162.3382.13239.5162.148.7
000000000006.58.3710.0332.57.500000000000000000
0.050.090.140.110.0600000.110.120.120.130.14012512568.87007.05000082.5147.6584.0328.7977.413.34229.6723.4318.11
0.80.760.881.182.122.481.837.926.345.618.2727.4426.4625.3223.05146.52153.41343.9117.6523.3329.1323.0429.0329.931.45359.12349.89406.02496.75512.55309.05696.97297.4334.98
1.150.220.180.07000000.490.40.280.14000083.2762.3415.460000091.7975.2261.96139.54260.33642.39.85518.07568.54
00000000000000000212.350000000235.48152.53123.3468.1932.227.097.738.5211.57
000000000000000.211.150.361.57.656.126.885.45.455.197.9260.8858.0997.26341.49222.98332.26191.76263.17236.84
1.150.220.180.07000000.490.40.280.1400.211.150.3357.1269.9921.586.885.45.455.197.92388.16285.83282.56549.22515.53981.64209.34789.75816.95
00000000.010.010.010.020.030.030.030.020.150.150.70.090.040.040.030.030.040.040.750.640.691.051.031.290.911.091.15
000.030.020.0100.010.050.040.040.080.060.080.090.10.160.152.520.130.170.240.30.380.480.562.562.352.52.552.412.42.22.32.43
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of LivaNova provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand LivaNova's financial health and stability.

Assets

LivaNova's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that LivaNova must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of LivaNova after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into LivaNova's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
198919901991199219931994199519961997199819992000null2001null2002nullnull20032004null2005null2006null2007null2008nullnull20092010null2011null2012null2013null2014nullnull201520162017201820192020202120222023
-1-3-3-5-5-7-10-11-14-12-3-24-3-26-245-2654-186-59-12-51-59-10-5126-1026784678364646365446575457-29-62-25-189-155-345-135-8617
000000000112132434434333333232232424354757208583697067514750
000000000000000000000000000000-411-412212222-5229-59-39-26-9-95-263721-114
0000000-1-1-3-516-5-116-8-1-8-84-8-1546-1596-29-20-400-4-70-10-7-6-10-6-10-8-103305-188-11129-31-34
000000000000000000371002001220712-1129422324122113239115012216556240307195183192
0000000000000000000002052553531010000000000779152832190
000000000000000000000000000000111113143154152247392627-1310
-1-2-3-4-5-6-9-12-14-14-8-5-8-23-51-2313-43-70-4-20-7014-20241424424942754979755479795479-99091120-91-791026974
00000000-3-1-4-3-4-5-3-4-5-4-2-3-2-4-3-1-40-1-20-2-6-7-6-18-7-14-18-19-14-6-19-6-17-38-34-38-28-35-25-26-35
000-161102-7-3428-10-1-30-4-3-4-17-11-217-11-1170-1-20-2-6-11-6-22-11-36-22-34-36-9-34-916-44-52-120-41-4136-38-40
000-152102-7-313023213010-14-7021-7021000000-40-4-4-21-4-15-21-3-15-333-6-18-82-13-662-11-5
000000000000000000000000000000000000000000000000000
0000000000000601611-7181-7481-74-50-7-50-43-8-43-7-80-700000-20-471129171406-48728426
21626000185018458245626131813251892509303010-391-23-39-62-23-51-62-510-465-57-6-45309-8-7
216260001850184589458981410141071014107-714-46-7-46-43-7-43-46-7-18-46-37-18-48-37-48-18-11811-42146310-18128021
000000000000000000000000000000000004025432533-24-5-13-18-50-342
000000000000000000000000000000000000000000000000000
1-125-34-6-1015-140-1-17405-1750-41453-4-7536-7-246-24-630-7730247-172420-1720-11-7253-4614191-4430762
-1.5-2.9-3.9-5.1-6-6.6-9.7-12.3-18.3-16.5-12.3-8.60-28.10-2.9001-7.70-75.20-22.1013.7021.90036.842.5057064.8035.107300-26.651.857.282.5-119.1-114.47743.439.9
000000000000000000000000000000000000000000000000000

LivaNova stock margins

The LivaNova margin analysis displays the gross margin, EBIT margin, as well as the profit margin of LivaNova. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for LivaNova.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the LivaNova's sales revenue. A higher gross margin percentage indicates that the LivaNova retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the LivaNova's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the LivaNova's total revenue generated. When comparing the revenue margin year over year, investors can gauge the LivaNova's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the LivaNova. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the LivaNova's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

LivaNova Margin History

LivaNova Gross marginLivaNova Profit marginLivaNova EBIT marginLivaNova Profit margin
2028e66.86 %24.63 %18.33 %
2027e66.86 %22.64 %16.89 %
2026e66.86 %19.72 %15.46 %
2025e66.86 %18.69 %15.02 %
2024e66.86 %17.84 %13.86 %
202366.86 %4.94 %1.52 %
202269.21 %7.98 %-8.44 %
202168.19 %4.54 %-13.12 %
202063.66 %-5.8 %-37.34 %
201966.76 %5.43 %-14.54 %
201866.35 %8.03 %-17.11 %
201764.39 %12.54 %-2.48 %
201657.99 %9.22 %-6.51 %
201564.11 %9.99 %-7.12 %
201490.63 %33.39 %19.84 %
201390.3 %31.01 %19.46 %
201291.39 %30.81 %18.23 %
201191 %27.89 %16.51 %
201087.91 %25.83 %24.53 %
200987.54 %21.97 %46.76 %
200886.04 %13.22 %18.61 %
200782.6 %-6.79 %-8.53 %
200686.06 %-37.82 %-39.08 %
200587.18 %-47.98 %-47.85 %
200484.85 %-18.65 %-17.99 %

LivaNova Stock Sales Revenue, EBIT, Earnings per Share

The LivaNova earnings per share therefore indicates how much revenue LivaNova has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue LivaNova earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates LivaNova's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of LivaNova’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating LivaNova's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LivaNova Revenue, EBIT and net profit per share

DateLivaNova Sales per ShareLivaNova EBIT per shareLivaNova Earnings per Share
2028e27.55 undefined0 undefined5.05 undefined
2027e26.34 undefined0 undefined4.45 undefined
2026e25.69 undefined0 undefined3.97 undefined
2025e24.33 undefined0 undefined3.65 undefined
2024e23.13 undefined0 undefined3.2 undefined
202321.28 undefined1.05 undefined0.32 undefined
202219.11 undefined1.53 undefined-1.61 undefined
202120.45 undefined0.93 undefined-2.68 undefined
202019.23 undefined-1.12 undefined-7.18 undefined
201922.42 undefined1.22 undefined-3.26 undefined
201822.83 undefined1.83 undefined-3.91 undefined
201721.02 undefined2.64 undefined-0.52 undefined
201619.75 undefined1.82 undefined-1.29 undefined
201512.7 undefined1.27 undefined-0.9 undefined
201410.95 undefined3.66 undefined2.17 undefined
201310.27 undefined3.18 undefined2 undefined
20129.08 undefined2.8 undefined1.66 undefined
20117.72 undefined2.15 undefined1.27 undefined
20106.66 undefined1.72 undefined1.63 undefined
20095.85 undefined1.28 undefined2.73 undefined
20085.21 undefined0.69 undefined0.97 undefined
20074.56 undefined-0.31 undefined-0.39 undefined
20065.13 undefined-1.94 undefined-2.01 undefined
20054.95 undefined-2.38 undefined-2.37 undefined
20044.3 undefined-0.8 undefined-0.77 undefined

LivaNova business model

LivaNova PLC is a global medical technology company specializing in the development and manufacturing of devices and therapies for cardiovascular diseases, epilepsy, and brain disorders. The company was founded in 2015 through the merger of Sorin Group and Cyberonics, and in 2019, a legal dispute resulted in the agreement to make compensation payments. The company is divided into three main divisions: cardiac surgery, neuromodulation, and cardiac rhythm management. Each division offers different products for their target markets. The cardiac surgery division provides devices for surgical treatment of cardiovascular diseases, such as heart valve repair and replacement systems, cardioplegia systems for heart cooling during surgery, and mechanical heart support systems for patients with severe heart failure. Neuromodulation specializes in the treatment of epilepsy, brain injuries, and psychiatric disorders. The division offers both implantable devices directly implanted in the brain and external devices that use magnetic fields to influence brain activity. The cardiac rhythm management division focuses on the treatment of heart rhythm disorders and offers pacemakers, implantable cardioverter-defibrillators (ICDs), catheters, and ablation systems to correct electrical changes in the heart. LivaNova is headquartered in London and has manufacturing facilities in North America, Europe, and Asia. The company works closely with clinical partners worldwide to understand the medical needs of patients and develop new products and therapies aimed at improving patients' lives. Overall, LivaNova's business model is centered around commitment to innovation, production, and global presence. The company aims to improve the quality of healthcare and provide better therapies and devices to patients worldwide. The focus of product development is often a balance of effectiveness, safety, and patient comfort. The answer is: LivaNova is a global medical technology company specializing in the development and manufacturing of devices and therapies for cardiovascular diseases, epilepsy, and brain disorders. LivaNova is one of the most popular companies on Eulerpool.com.

LivaNova SWOT Analysis

Strengths

LivaNova PLC has several strengths that contribute to its competitive advantage in the industry. Firstly, the company has a strong portfolio of innovative medical technology products, allowing it to meet the diverse needs of patients and healthcare professionals. This enables LivaNova to stay ahead of its competitors and maintain a strong market position. Secondly, the company has a global presence, with operations in various countries, which provides it with access to a wide customer base and opportunities for growth. Additionally, LivaNova has a talented and experienced workforce, enabling it to develop and deliver high-quality products and services.

Weaknesses

Despite its strengths, LivaNova PLC also faces certain weaknesses that need to be addressed. One major weakness is the company's heavy dependence on a few key products for a significant portion of its revenue. This exposes LivaNova to risks such as market fluctuations and potential product obsolescence. Another weakness is the company's limited presence in emerging markets, which hinders its ability to tap into the growing demand for medical technology in these regions. Moreover, LivaNova has faced challenges in effectively integrating acquired businesses, resulting in potential operational inefficiencies.

Opportunities

LivaNova PLC has several opportunities that can be capitalized on to drive growth and profitability. The increasing prevalence of chronic diseases and the aging population present a significant opportunity for the company to expand its product offerings and enter new markets. Additionally, the growing demand for minimally invasive surgeries and advanced medical treatments provides LivaNova with the chance to develop innovative solutions that cater to these trends. Furthermore, partnerships and collaborations with healthcare organizations and research institutions can enhance LivaNova's research and development capabilities, leading to new breakthrough products.

Threats

LivaNova PLC operates in an industry that is characterized by intense competition and regulatory challenges, posing threats to its business. The presence of strong competitors with established market positions and significant resources can make it difficult for LivaNova to gain market share. Moreover, the company is subject to strict regulations and compliance requirements, which can impact its ability to introduce new products and expand into certain markets. Additionally, economic downturns and fluctuations in healthcare spending can affect the demand for LivaNova's products and services, presenting a potential threat to its financial performance.

LivaNova Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

LivaNova Revenue by Segment

Segmente20172016
Cardiac Surgery635.52 M USD611.72 M USD
Neuromodulation374.98 M USD351.41 M USD
Cardiac Rhythm Management-249.07 M USD

LivaNova Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

LivaNova Revenue by Segment

DateEuropeRest of WorldU.SUnited KingdomUnited States
2023214.79 M USD303.71 M USD635.04 M USD41.5 M USD-
2022178.8 M USD271.45 M USD571.56 M USD32.3 M USD-
2021201.53 M USD262.54 M USD571.3 M USD35.8 M USD-
2020193.37 M USD272.24 M USD468.63 M USD29.7 M USD-
2019223.18 M USD314.5 M USD546.48 M USD37.7 M USD-
2018---34.8 M USD-
2017210.47 M USD307.08 M USD-30.8 M USD494.72 M USD
2016402.07 M USD321.35 M USD-37.3 M USD490.51 M USD

LivaNova Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

LivaNova historical P/E ratio, EBIT, and P/S ratio.

LivaNova shares outstanding

The number of shares was LivaNova in 2023 — This indicates how many shares 54.212 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue LivaNova earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates LivaNova's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of LivaNova’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating LivaNova's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for LivaNova.

LivaNova latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.8 0.93  (16.48 %)2024 Q2
3/31/20240.5 0.73  (47.06 %)2024 Q1
12/31/20230.79 0.87  (10.79 %)2023 Q4
9/30/20230.65 0.73  (12.53 %)2023 Q3
6/30/20230.55 0.78  (41.77 %)2023 Q2
3/31/20230.4 0.43  (7.39 %)2023 Q1
12/31/20220.75 0.81  (8.14 %)2022 Q4
9/30/20220.56 0.58  (4.28 %)2022 Q3
6/30/20220.53 0.53  (0.74 %)2022 Q2
3/31/20220.49 0.48  (-2.68 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the LivaNova stock

Eulerpool World ESG Rating (EESG©)

65/ 100

🌱 Environment

42

👫 Social

83

🏛️ Governance

70

Environment

Scope 1 - Direct Emissions
13,609
Scope 2 - Indirect emissions from purchased energy
8,965.9
Scope 3 - Indirect emissions within the value chain
2,604.7
Total CO₂ emissions
22,574.9
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

LivaNova list of shareholders

%
Name
Stocks
Change
Date
5.03414 % Millennium Management LLC2,733,540545,0054/9/2024
4.36837 % Barrow Hanley Global Investors2,372,02747,67212/31/2023
3.66067 % State Street Global Advisors (US)1,987,74436,19512/31/2023
3.23950 % The Vanguard Group, Inc.1,759,04923012/31/2023
2.84278 % AllianceBernstein L.P.1,543,62844,51412/31/2023
2.28727 % Dimensional Fund Advisors, L.P.1,241,98574,06712/31/2023
2.26393 % Greenlight Capital, Inc.1,229,31642,04012/31/2023
2.25603 % Geode Capital Management, L.L.C.1,225,02449,80712/31/2023
2.22188 % Columbia Threadneedle Investments (US)1,206,479318,36012/31/2023
2.11991 % Citadel Advisors LLC1,151,113482,59312/31/2023
1
2
3
4
5
...
10

LivaNova Executives and Management Board

Mr. Alex Shvartsburg53
LivaNova Chief Financial Officer
Compensation 2.13 M
Ms. Trui Hebbelinck51
LivaNova Chief Human Resource Officer
Compensation 1.69 M
Mr. William Kozy72
LivaNova Chairman of the Board, Interim Chief Executive Officer (since 2018)
Compensation 389,987
Mr. Todd Schermerhorn62
LivaNova Independent Director
Compensation 269,958
Mr. Francesco Bianchi66
LivaNova Independent Director
Compensation 262,958
1
2
3

LivaNova Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Omnicom Stock
Omnicom
SupplierCustomer0,560,410,62-0,01-0,260,84
Medistim Stock
Medistim
SupplierCustomer0,020,770,490,590,550,71
Alphabet A Stock
Alphabet A
SupplierCustomer-0,290,580,820,750,400,85
1

Most common questions regarding LivaNova

What values and corporate philosophy does LivaNova represent?

LivaNova PLC is a renowned company that upholds strong values and a distinctive corporate philosophy. With a commitment to improving patients' lives, LivaNova PLC focuses on delivering innovative medical solutions to enhance healthcare outcomes. The company believes in prioritizing patients' well-being, collaborating with healthcare professionals, and fostering a culture of excellence to drive positive change in the industry. LivaNova PLC's dedication to integrity, teamwork, and patient-centricity has earned them recognition as a trusted global leader in medical technology.

In which countries and regions is LivaNova primarily present?

LivaNova PLC is primarily present in numerous countries and regions worldwide. The company has a strong global presence and operates in key markets such as the United States, Europe, Asia Pacific, and the Middle East. With its headquarters in London, United Kingdom, LivaNova PLC has established a significant presence in these regions, leveraging its expertise in medical technology and innovative solutions. By focusing on these strategic markets, LivaNova PLC aims to provide its cutting-edge products and therapies to patients and healthcare professionals across the globe.

What significant milestones has the company LivaNova achieved?

LivaNova PLC, a renowned company in the stock market, has accomplished several significant milestones. Firstly, the company successfully developed and launched its groundbreaking VNS Therapy System, a revolutionary treatment for drug-resistant epilepsy and depression. LivaNova PLC also expanded its reach by acquiring TandemLife, a leading provider of advanced cardiopulmonary support solutions. Additionally, the company achieved FDA approval for several innovative medical devices, including the Perceval Sutureless Heart Valve and the SenTiva VNS Therapy System. LivaNova PLC's commitment to continuous innovation and exceptional healthcare solutions has led to remarkable advancements and cemented its position as an industry leader.

What is the history and background of the company LivaNova?

LivaNova PLC is a renowned global medical technology company, specializing in the development and delivery of innovative healthcare solutions. Established in 2015, LivaNova was formed as a result of a merger between Sorin Group, an established leader in the cardiac surgery market, and Cyberonics, a pioneer in the field of neuromodulation. With a rich history spanning decades, LivaNova PLC continues to make significant contributions in the areas of cardiovascular and neuromodulation therapies, aiming to improve patient outcomes and quality of life. The company is committed to advancing medical technology through continual research and development efforts, offering a diverse portfolio of products and services to address a wide range of medical needs.

Who are the main competitors of LivaNova in the market?

Some of the main competitors of LivaNova PLC in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.

In which industries is LivaNova primarily active?

LivaNova PLC is primarily active in the industries of medical devices and therapies.

What is the business model of LivaNova?

The business model of LivaNova PLC focuses on developing and commercializing innovative medical technology solutions in the fields of cardiovascular and neuromodulation. As a global medical device company, LivaNova PLC is committed to enhancing patient outcomes and transforming patients' lives. Their diverse product portfolio includes advanced devices and therapies for cardiac surgery, heart failure, and other cardiovascular conditions, as well as treatments for epilepsy and depression. Through research, development, and strategic collaborations, LivaNova PLC aims to provide healthcare professionals with effective solutions to improve patient care and quality of life.

What is the P/E ratio of LivaNova 2024?

The LivaNova P/E ratio is 15.81.

What is the P/S ratio of LivaNova 2024?

The LivaNova P/S ratio is 2.19.

What is the AlleAktien quality score of LivaNova?

The AlleAktien quality score for LivaNova is 3/10.

What is the revenue of LivaNova 2024?

The expected LivaNova revenue is 1.26 B USD.

How high is the profit of LivaNova 2024?

The expected LivaNova profit is 174.02 M USD.

What is the business model of LivaNova

LivaNova PLC is a global medical technology company that develops, manufactures, and distributes innovative solutions for patients with cardio-pulmonary disease as well as for neuromodulation and neurosurgery applications. It was formed in 2015 as a merger between the Italian Sorin Group and the US-based Cyberonics and is headquartered in London. LivaNova's business model is focused on advancing medical progress through technology, innovation, and collaboration with leading clinical partners. The company operates in three main areas: cardiology, neuromodulation, and neurosurgery. LivaNova's cardiology division focuses on developing products and procedures for the treatment of cardiovascular diseases. These include artificial heart valves and surgical instruments for procedures such as bypass surgeries and trans-septal interventional procedures. These products are used in patients with congenital heart defects, coronary artery disease, and valve diseases. The neuromodulation division of LivaNova includes the development of implantable devices for the treatment of epilepsy and depression. The company is well positioned to benefit from the growing markets for neuromodulatory therapies. One product from LivaNova is the vagus nerve stimulator, which is used for the treatment of epilepsy, depression, and other neurological disorders. LivaNova's neurosurgery division specializes in the development of devices and technologies for the treatment of brain diseases and injuries. This includes invasive neurostimulators, devices for cerebral temperature measurement, and devices for monitoring brain functions during surgeries. These products are used by neurosurgeons and neurologists for the diagnosis and treatment of patients with brain diseases and injuries. LivaNova is committed to continuously developing and improving new products and services to meet the needs of healthcare facilities and patients. The company works closely with leading clinical partners to test and enhance the effectiveness of its products. Collaboration with universities, medical centers, and other research institutions allows LivaNova to share its technology and expertise with leading clinics worldwide, maximizing the potential of its products and services. The company also provides innovative digital solutions to support patients with cardiovascular and neurological diseases. The MyLivaNova platform serves as a tool for patients to take control of their health and collaborate closely with their doctors and healthcare professionals. LivaNova's business model is focused on positioning the company as a leading provider of medical technology products and services. The company is committed to improving people's lives through innovative technologies and treatment options. With a wide range of products and a strong presence in the global market, LivaNova is well positioned to continue growing and remaining innovative in the coming years.

What is the LivaNova dividend?

LivaNova pays a dividend of 0 USD distributed over payouts per year.

How often does LivaNova pay dividends?

The dividend cannot currently be calculated for LivaNova or the company does not pay out a dividend.

What is the LivaNova ISIN?

The ISIN of LivaNova is GB00BYMT0J19.

What is the LivaNova WKN?

The WKN of LivaNova is A14156.

What is the LivaNova ticker?

The ticker of LivaNova is LIVN.

How much dividend does LivaNova pay?

Over the past 12 months, LivaNova paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, LivaNova is expected to pay a dividend of 0 USD.

What is the dividend yield of LivaNova?

The current dividend yield of LivaNova is .

When does LivaNova pay dividends?

LivaNova pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of LivaNova?

LivaNova paid dividends every year for the past 0 years.

What is the dividend of LivaNova?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is LivaNova located?

LivaNova is assigned to the 'Health' sector.

Wann musste ich die Aktien von LivaNova kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of LivaNova from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did LivaNova pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of LivaNova in the year 2023?

In the year 2023, LivaNova distributed 0 USD as dividends.

In which currency does LivaNova pay out the dividend?

The dividends of LivaNova are distributed in USD.

All fundamentals about LivaNova

Our stock analysis for LivaNova Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of LivaNova Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.